MedPath

Allovir and Kalaris Therapeutics Merge to Focus on Retinal Disease Therapies

• Allovir Inc. will merge with Kalaris Therapeutics Inc., shifting focus to therapies for neovascular and exudative retinal diseases. • The combined company, Kalaris Therapeutics Inc. (KLRS), will advance TH-103, an anti-VEGF treatment, currently in a Phase I study for neovascular age-related macular degeneration (nAMD). • Phase I study data readout for TH-103 is anticipated in the third quarter of 2025, marking a key milestone for the merged entity's pipeline. • The strategic merger aims to address conditions like nAMD, diabetic macular edema, and retinal vein occlusion, leveraging Kalaris' existing assets.

Allovir Inc. is set to merge with Kalaris Therapeutics Inc., a privately held company, to pivot towards developing treatments for neovascular and exudative retinal diseases. This strategic move comes as Allovir seeks a new direction following challenges faced since late December.
The merger will result in the combined entity being named Kalaris Therapeutics Inc., and its shares will be traded on Nasdaq under the ticker symbol KLRS. A key asset in Kalaris' portfolio is TH-103, an anti-VEGF treatment currently undergoing a Phase I study. Data from this study is expected in the third quarter of 2025.
The primary focus of the merged company will be to advance the development of TH-103 for treating neovascular age-related macular degeneration (nAMD), diabetic macular edema, and retinal vein occlusion. The ongoing Phase I study is specifically evaluating TH-103 as a treatment for nAMD.
This merger represents a significant shift in strategic direction, leveraging Kalaris' existing assets to target prevalent retinal diseases.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Karyopharm's Selinexor Shows Promise in Myelofibrosis, Phase 3 Data Expected in 2H 2025

Karyopharm Therapeutics anticipates top-line results from its Phase 3 SENTRY trial of selinexor plus ruxolitinib for JAKi-naïve myelofibrosis in the second half of 2025.
The SENTRY trial updated its co-primary endpoint to absolute mean change in total symptom score (Abs-TSS) and increased the sample size to 350 patients.

Novartis and MMV Advance Novel Malaria Drug Combination into Phase 3 Trials

Novartis and Medicines for Malaria Venture (MMV) are progressing a new drug combination of ganaplacide and lumefantrine into Phase 3 trials to combat resistant malaria infections.
The novel non-artemisinin regimen aims to treat uncomplicated Plasmodium falciparum malaria with a once-daily solid dispersion formulation (SDF).

Phase 3 Trial Success Paves Way for CSL's Rare Disease Drug Filing

CSL's phase 3 trial of garadacimab, a monthly therapy for hereditary angioedema (HAE), shows promising results, positioning it as a strong competitor to Takeda's Takhzyro. The study highlights garadacimab's efficacy and convenience, with significant reductions in monthly attacks and a favorable safety profile.

Valo Health Halts Development of Eye Disease Drug, Seeks Partnership

Valo Health has decided to discontinue the independent development of its diabetic retinopathy drug candidate, OPL-0401, following a phase 2 trial. The company is now looking for a partner to advance the program, despite the drug not meeting the primary or secondary endpoints in the SPECTRA trial. However, Valo remains optimistic about the drug's potential in preventing disease progression and will focus on its Opal computational drug discovery platform for future therapies.

Galera Therapeutics Completes Acquisition of Nova Pharmaceuticals

Galera Therapeutics, Inc. has finalized its acquisition of Nova Pharmaceuticals, Inc., a move that shifts Galera's development strategy towards anti-cancer therapeutics, particularly for advanced breast cancer. The acquisition is supported by a $3 million investment from a syndicate led by Ikarian Capital. Galera's new lead program involves a Phase 1/2 trial of a pan-NOS Inhibitor combined with standard treatments for metaplastic breast cancer, with operations funded into 2026.

Palvella Therapeutics Gains Analyst Attention with QTORIN Rapamycin Development for Rare Skin Diseases

Palvella Therapeutics is developing QTORIN 3.9% rapamycin anhydrous gel for rare genetic skin diseases, addressing unmet needs.
Phase 3 trial data for microcystic lymphatic malformations (mLMs) is expected in early 2026, with potential market launch in 2027.

FDA Accepts Alnylam's Vutrisiran Application for ATTR Amyloidosis with Cardiomyopathy

The FDA has accepted Alnylam's sNDA for vutrisiran to treat ATTR amyloidosis with cardiomyopathy, setting a PDUFA date of March 23, 2025.
The application is based on Phase 3 HELIOS-B trial results, which demonstrated favorable cardiovascular outcomes and improved survival in ATTR-CM patients.

Ocuphire Pharma Acquires Opus Genetics, Expanding Gene Therapy Pipeline for Inherited Retinal Diseases

Ocuphire Pharma has acquired Opus Genetics in an all-stock transaction, with the combined company renamed Opus Genetics, Inc., focusing on inherited retinal diseases.
The acquisition expands the pipeline to include AAV-based gene therapies for IRDs and phentolamine ophthalmic solution for presbyopia, while seeking a partner for diabetic retinopathy program.

Insitro and Lilly Partner to Develop AI-Discovered Metabolic Disease Drugs

Insitro and Eli Lilly are collaborating to develop treatments for metabolic diseases, leveraging Insitro's AI platform to identify novel drug targets.
The partnership focuses on gene-silencing siRNA molecules and antibody development, with Insitro responsible for running clinical trials.

OnKure Therapeutics Advances Mutant-Specific PI3Kα Inhibitor OKI-219 Following Merger

OnKure Inc. and Reneo Pharmaceuticals have completed a merger, resulting in OnKure Therapeutics, which now trades on the Nasdaq under the ticker symbol 'OKUR'.
The merger includes a $65 million private placement to support the clinical development of OnKure's drug pipeline, extending the company's cash runway into Q4 2026.

Reference News

[1]
Allovir sees a new direction with Kalaris merger - BioWorld
bioworld.com · Nov 9, 2024

Allovir Inc. merges with Kalaris Therapeutics Inc. to develop therapies for neovascular and exudative retinal diseases. ...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy